Medical Advocates
Efavirenz (Sustiva/Strocrin)
 
Journal Citations: Adult/
Adolescent Treatment

General  Reports
 Quality of Life
CNS Benefits
 Efficacy
 Treatment Strategies
 Drug Failure
 Drug Comparison Studies


 
Efavirenz Main Page Main New/Newsworthy  Home Page      
Last Update:  January 07, 2012
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
           
 
A WEEK-IN REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation
and Associations with CD4 Cell Rises in HIV-Infected Patients.
Funderburg N, Kalinowska M, Eason J, et al  
PLoS One. 2010 Oct 6;5(10). pii: e13188.
 Paper

Change in High-Sensitivity C-Reactive Protein (hsCRP) Levels following Initiation of Efavirenz-
Based Antiretroviral Regimens in HIV-infected Individuals.
 Shikuma C, Ribaudo HJ, Zheng Y, et al
AIDS Res Hum Retroviruses. 2010 Sep 23.
 Abstract

Quantifying the risks and benefits of efavirenz use in HIV-infected women of
childbearing age in the USA.
 Hsu H, Rydzak C, Cotich K,  et al;
HIV Med. 2010 Jun 17.
 Abstract

The relation between treatment outcome and efavirenz, atazanavir or lopinavir
exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
Josephson F, Andersson MC, Flamholc L, et al 
Eur J Clin Pharmacol. 2010 Apr;66(4):349-57
 Abstract

A WEEK IN REVIEW FEATURED REPORT
Efavirenz - Still First-line King?
 Best BM, Goicoechea M. 
Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):965-972.
 Abstract
 
Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection:
case report and review of the literature.
 Torno MS, Witt MD, Saitoh A, Fletcher CV.  
Pharmacotherapy. 2008 Jun;28(6):782-7.
 Abstract
 
Response to Efavirenz-Containing Regimens in Previously Antiretroviral-Naive HIV-Positive
Patients: The Role of Gender.
 Smith CJ, Sabin CA, Youle MS, et al 
J Acquir Immune Defic Syndr. 2007 Jul 19;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Efavirenz.
 Maggiolo F
Expert Opin Pharmacother. 2007 Jun;8(8):1137-45.
 Abstract

Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women)
in West Africa.
 Danel C, Moh R, Anzian A, Abo Y, et al   
J Acquir Immune Defic Syndr. 2006 May;42(1):29-35.
Abstract
Quality of Life Studies
           
 
Virologic Suppression, Treatment Adherence, and Improved Quality of Life on a Once-Daily
Efavirenz-Based Regimen in Treatment-Naïve HIV-1-Infected Patients Over 96 Weeks.
Jayaweera D, Dejesus E, Nguyen KL, et al 
HIV Clin Trials. 2009 Nov-Dec;10(6):375-84
 Abstract

Quality of Life, Emotional Status, and Adherence of HIV-1–Infected Patients Treated With Efavirenz.
Fumaz CR, Tuldra A, Ferrer MJ, et al.  
 J Acquir Immune Defic Syndr 2002 Mar1;29(3):244-53
Abstract
Central Nervous System Benefits
 
  Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous
system in HIV-1-infected patients.
von Giesen HJ, Koller H, Theisen A, Arendt G.
J Acquir Immune Defic Syndr 2002 Apr 1;29(4):363-7
 Abstract		  
Efficacy
General Studies                    HIV/TB

General  HIV Studies

 
A WEEK-IN-REVIEW FEATURED REPORT
 Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials
Relative to ART-CC Cohort Study.
 Mugavero MJ, May M, Ribaudo HJ, et al
J Acquir Immune Defic Syndr. 2011 Aug 18
Abstract

Failure of Initial Therapy With Two Nucleosides and Efavirenz Is Not Associated With Early
Emergence of Mutations in the C-Terminus of HIV-1 Reverse Transcriptase.
Brehm JH, Lalama CM, Hughes MD, et al
J Acquir Immune Defic Syndr. 2011 Apr;56(4):344-348.
 Abstract

Minimum effective plasma concentration of efavirenz in treatment-naive Chinese HIV-infected patients.
 Sun J, Chen J, Yao Y, et al
 Int J STD AIDS. 2010 Dec;21(12):810-3.
 Abstract

Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the
Treatment of Antiretroviral-Naive
Subjects with CCR5-Tropic HIV-1 Infection.
 Cooper DA, Heera J, Goodrich J,  et al
J Infect Dis. 2010 Feb 12.
 Abstract

A WEEK-IN REVIEW FEATURED REPORT
Prospective, Randomized, Open Label Trial of Efavirenz vs Lopinavir/Ritonavir
in HIV+ Treatment-Naive Subjects With CD4+<200 cell/mm3 in Mexico.
 Sierra-Madero J, Villasis-Keever A, Méndez P,et al
J Acquir Immune Defic Syndr. 2010 Jan 20
 Abstract

Efavirenz in the therapy of HIV infection.
Rakhmanina NY, van den Anker JN.
Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):95-103
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
The relation between treatment outcome and efavirenz, atazanavir or lopinavir
exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.
 Josephson F, Andersson MC, Flamholc L, et al
Eur J Clin Pharmacol. 2009 Dec 5.
 Abstract

The Nucleoside Backbone Affects Durability of Efavirenz- or Nevirapine-Based Highly Active
Antiretroviral Therapy in Antiretroviral-Naive Individuals.
 Annan NT, Nelson M, Mandalia S, et al  
 J Acquir Immune Defic Syndr. 2009 Apr 6
 Abstract

Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients:
Case reports from Abidjan, Côte d'Ivoire.
Borget MY, Diallo K, Adje-Toure C, et al
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA
levels and CD4 cell counts.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al
J Infect Dis. 2008 Apr 1;197(7):1006-10
 Abstract
 
Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast).
 Tanon AK, Eholié SP, Polneau S, et a
Med Mal Infect. 2008 Apr 3
Abstract
 
A WEEK IN REVIEW FEATURED REPORT
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside
analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
 Domingo P, Suárez-Lozano I, Torres F, et al
J Antimicrob Chemother. 2008 Mar 20
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase
inhibitors for HIV-1 infection.
 Tashima K, Staszewski S, Nelson M, et al
AIDS. 2008 Jan 11;22(2):275-279.
Abstract
 
Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with
and without Food, as Initial Therapy for HIV Infection: The ELADI Study.
 Sánchez-Conde M, Palacios R, Sanz J, et al
AIDS Res Hum Retroviruses. 2007 Oct;23(10):1237-1241.
 Abstract
 
Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination
with efavirenz: results of a systematic overview.
Bartlett JA, Chen SS, Quinn JB. 
HIV Clin Trials. 2007 Jul-Aug;8(4):221-6.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination
with efavirenz: results of a systematic overview.
 Bartlett JA, Chen SS, Quinn JB. 
HIV Clin Trials. 2007 Jul-Aug;8(4):221-6.
 Abstract
 
Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or
efavirenz at a university-based outpatient service in Brazil.
 Vanni T, Morejón KM, Santana RC, et al 
Braz J Med Biol Res. 2007 Jul;40(7):963-9.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Plasma HIV-1 RNA Dynamics in Antiretroviral-Naive Subjects Receiving either Triple-Nucleoside
or Efavirenz-Containing Regimens: ACTG A5166s
 Kuritzkes DR, Ribaudo HJ, Squires KE, et al
J Infect Dis. 2007 Apr 15;195(8):1169-76.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line
therapy for all?
 Goicoechea M, Best B.
Expert Opin Pharmacother. 2007 Feb;8(3):371-82
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
A Comparison between Abacavir and Efavirenz as the Third Drug Used in Combination with a
Background Therapy Regimen of 2 Nucleoside Reverse-Transcriptase Inhibitors in Patients with
Initially Suppressed Viral Loads.
 Cozzi-Lepri A, Luca AD, Phillips AN, et al 
J Infect Dis. 2006 Jul 1;194(1):20-8.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or
lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
 Panagopoulos P, Tsiodras S, Antoniadou A, et al
Clin Microbiol Infect. 2006 May;12(5):486-9.
 Abstract
 
Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort).
 Harmann M, Witte S, Brust J, et al
Int J STD AIDS. 2005 Jun;16(6):404-9
Abstract
 
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of
nevirapine or efavirenz-based first-line HAART.
 van Leth F, Andrews S, Grinsztejn B, Wilkins E
 AIDS. 2005 Mar 25;19(5):463-471
 Abstract
 
Plasma HIV-1 RNA Decline Within the First Two Weeks of Treatment Is Comparable
for Nevirapine, Efavirenz, or Both Drugs Combined and Is Not Predictive of Long-Term
Virologic Efficacy: A 2NN Substudy.
 van Leth F, Huisamen CB, Badaro R, et al
J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):296-300.
 Abstract
 
First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for
naive patients.
 Manfredi R, Calza L, Chiodo F.
 AIDS. 2004 Nov 19;18(17):2331-3.
 Abstract
 
Clinical, Virologic, and Immunologic Response to Efavirenz-or Protease Inhibitor-Based
Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive Patients With Advanced
HIV Infection (EfaVIP 2 Study).
 The EfaVIP Cohort Study Group.
J Acquir Immune Defic Syndr. 2004 Apr 20;35(4):343-350.
 Abstract
 
Efavirenz Versus Nevirapine in Current Clinical Practice: A Prospective, Open-Label
Observational Study.
 Manfredi R, Calza L, Chiodo F. 
J Acquir Immune Defic Syndr. 2004 Mar 15;35(5):492-502.
 Abstract
 
FULL-TEXT ARTICLE
 Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive
Patients Infected with HIV-1
 van Leth F , Phanuphak P Stroes  E , et al  
PLoS Medicine Vol 1, No 1
 Paper
 
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of
HIV-1 infection.
 Gulick RM, Ribaudo HJ, Shikuma CM  
N Engl J Med. 2004 Apr 29;350(18):1850-61.
Abstract
 
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or
both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
 Van Leth F, Phanuphak P, Ruxrungtham K, et al.  
 Lancet. 2004 Apr 17;363(9417):1253-1263.
 Abstract
 
Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in
antiretroviral-naive patients with advanced HIV infection.
 Manosuthi W, Sungkanuparph S, Vibhagool A, et al
HIV Med. 2004 Mar;5(2):105-9.
 Abstract
 
FULL-TEXT ARTICLE
Virological and immunological outcomes in HIV-1-infected Chinese patients treated with a
combination of Efavirenz and Indinavir for 48 weeks.
 Li L, Wei FL, Mei S, et al
Chin Med J (Engl). 2004 Mar;117(3):347-52
 Abstract
 
Intrapatient Variability of Efavirenz Concentrations as a Predictor of Virologic
Response to Antiretroviral Therapy.
 Brundage RC, Yong FH, Fenton T, et al
Antimicrob Agents Chemother. 2004 Mar;48(3):979-984
 Abstract

.
Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy
is effective and well tolerated.
 Portsmouth S, Imami N, Pires A, et al  
HIV Med. 2004 Jan; 5(1): 26-9.
Abstract
 
A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens versus a 3-Drug
Regimen, in Advanced Human Immunodeficiency Virus Disease.
Fischl MA, Ribaudo HJ, Collier AC, et al
J Infect Dis. 2003 Sep 1;188(5):625-34.
 Abstract
 
 
 

A prospective comparison of the two main indications of efavirenz in 2001 highly active
antiretroviral therapy (HAART) regimens: first-line versus salvage use.
 Manfredi R, Calza L, Chiodo F.
 J Antimicrob Chemother 2002 May;49(5):723-9
 Abstract

Evaluation of an efavirenz-containing regimen: an open-label, multicenter study.
 Hartmann M, Rump A, Brust J, et al
 HIV Clin Trials 2001 Sep-Oct;2(5):421-8
 Abstract

Efavirenz as a substitute for protease inhibitors in hiv-1-infected patients with undetectable
plasma viral load on haart: a median follow-up of 64 weeks. 
Rey D, Schmitt MP, Partisani M, et al.
J Acquir Immune Defic Syndr 2001 Aug 15;27(5):459-62
Abstract

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
Albrecht MA,  Bosch RJ, Hammer SM, et al;
N Engl J Med 2001  Aug 9;345(6):398-407
 Abstract

Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy
The Swiss HIV Cohort Study.
Friedl AC, Ledergerber B, Flepp M, et al
 AIDS 2001 Sep 28;15(14):1793-1800
 Abstract

Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir
and saquinavir, or efavirenz.
Lucas GM, Chaisson RE, Moore RD.
AIDS 2001 Sep 7;15(13):1679-1686
 Abstract
 

  
HIV/HCV Studies
 
  Effect of Treatment With Efavirenz on Neuropsychiatric Adverse Events of Interferon in HIV/HCV-Coinfected Patients.
 Quereda C, Corral I, Moreno A, Pérez-Elías MJ,
J Acquir Immune Defic Syndr. 2008 Jul 23.
Abstract
 
HIV/TB Studies
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving
rifampicin: 48 weeks results.
 Manosuthi W, Kiertiburanakul S, Sungkanuparph S, et al 
AIDS. 2006 Jan 2;20(1):131-132.
 Abstract

Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving
|highly active antiretroviral therapy and rifampicin.
 Manosuthi W, Sungkanuparph S, Thakkinstian A, et al
AIDS. 2005 Sep 23;19(14):1481-6.
 Abstract

Drug Failure
       
 
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms
are associated with early discontinuation of efavirenz-containing regimens.
 Wyen C, Hendra H, Siccardi M, et al
J Antimicrob Chemother. 2011  2011 Jun 29.
 Abstract

How Long Is the Window of Opportunity Between Adherence Failure and Virologic Failure on Efavirenz-Based
HAART?
 Gross R, Bilker WB, Wang H, Chapman J.
HIV Clin Trials. 2008 May-June 1;9(3):202-206.
 Abstract
Drug Comparison Studies
       
 
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized,
double-blind SENSE trial.
Fätkenheuer G, Duvivier C, Rieger A,  et al
J Antimicrob Chemother. 2011 Dec 29.
 Abstract

Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine
for Treatment-Naive Human Immunodeficiency Virus-1-Infected Patients: 156-Week Results From STARTMRK.
Rockstroh JK, Lennox JL, Dejesus E,  et al
Clin Infect Dis. 2011 Oct;53(8):807-816.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).
Nguyen A, Calmy A, Delhumeau C, et al
AIDS. 2011 May 17
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine
clinical practice in Europe: a EuroSIDA study.
 Reekie J, Reiss P, Ledergerber B, Sedlacek D, et al
HIV Med. 2010 Aug 31
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients:
96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses.
Lennox JL, Dejesus E, Berger DS,  et al
J Acquir Immune Defic Syndr. 2010 Apr 15
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Similar Antiviral Efficacy and Tolerability Between Efavirenz and Lopinavir/Ritonavir,
Administered With Abacavir/Lamivudine (Kivexa), in Antiretroviral-Naïve Patients:
A 48-Week, Multicentre, Randomized Study (Lake Study).
 Echeverría P, Negredo E, Carosi G,et al  
Antiviral Res. 2009 Nov 23.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
 Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy
for patients with HIV.
 Young J, Bucher HC, Guenthard HF, et al
Antivir Ther. 2009;14(6):771-779.
 Abstract

Observational Study to Evaluate Clinical, Immunological, and Virological Outcomes
After First-Line Highly Active Antiretroviral Therapy With a Regimen Including
Either Efavirenz or Lopinavir-Ritonavir in Naive Patients in Clinical Practice.
 Pérez-Elías MJ, Moreno A, Casado JL, et al 
JIAPAC 2009 Aug 31.
 Abstract

Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes
in Southern African adults.
 Nachega JB, Hislop M, Dowdy DW, et al   
 AIDS. 2008 Oct 18;22(16):2117-25.
 Abstract

Virologic, Immunologic, Clinical, Safety, and Resistance Outcomes from a Long-Term
Comparison of Efavirenz-Based Versus Nevirapine-Based Antiretroviral Regimens as Initial
Therapy in HIV-1-Infected Persons.
 van den Berg-Wolf M, Hullsiek KH, Peng G, et al
HIV Clin Trials. 2008 Jan 1;9(5):324-336
 Abstract
 
Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast).
 Tanon AK, Eholié SP, Polneau S, et al
Med Mal Infect. 2008 Apr 3
Abstract

Efavirenz Main Page Main New/Newsworthy  Home Page      

Efavirenz Journal Citations: Adult/Adolescent Treatment